FTM
BECOME A MEMBER
() () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () ()

Tag Archives: Biopharmaceutical

  • Home
  •  | 
  • Tag Archives: "Biopharmaceutical"

Pivot Completes C$1.64 Million Non-Brokered Private Placement

Pivot Completes C$1.64 Million Non-Brokered Private Placement
VANCOUVER, Oct. 22, 2018 /CNW/ - Pivot Pharmaceuticals Inc. (CSE: PVOT / OTCQB: PVOTF / FRA: NPAT) ("Pivot" or the "Company") is pleased to announce that it has closed a non-brokered Private Placement (the "Private Placement") for a total of C$1,641,300 and has also settled C$1,500,000 of outstanding debt with the issuance of common shares and share purchase warrant. Proceeds of the Private Placement will be used for general working capital purposes, capital expenditures and patent costs.
Read more

GB Sciences’ Dr. Andrea Small-Howard Presents Results of GB Sciences’ Novel Pain Formulation Research at UCLA during CannMed 2018

GB Sciences’ Dr. Andrea Small-Howard Presents Results of GB Sciences’ Novel Pain Formulation Research at UCLA during CannMed 2018
GB Sciences' Dr. Andrea Small-Howard Presents Results of GB Sciences' Novel Pain Formulation Research at UCLA during CannMed 2018 Dr. Small-Howard explains the mechanisms for the treatment of chronic and neuropathic pain using proprietary, cannabis-based formulations LAS VEGAS, Oct. 9, 2018 /CNW/ -- GB Sciences, Inc. (OTCQB: GBLX) announces that their Chief Science Officer, Dr. Andrea Small-Howard (http://www.cannmedevents.com/andrea-small-howard/), will…
Read more

Nemus Bioscience Announces that Emerald Health Sciences has Provided a Credit Facility of up to $20 Million and Adopted an Open Market Share Purchase Program of up to 10 Million Common Shares

Nemus Bioscience Announces that Emerald Health Sciences has Provided a Credit Facility of up to $20 Million and Adopted an Open Market Share Purchase Program of up to 10 Million Common Shares
LONG BEACH, CA, Oct. 08, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Nemus Bioscience, Inc. (OTCQB: NMUS), focused on the development of bioengineered cannabinoid-based therapeutics to address global medical indications, announced today that the Company’s majority shareholder, Emerald Health Sciences, Inc. (EHS), will provide the Company with a credit facility of up to $20 million for operating purposes and has committed to purchase up to 10 million shares of Nemus common stock in the open market. The Board of Directors of Nemus also appointed Dr. Avtar Dhillon, MD, as Executive Chairman of the Board effective October 8, 2018.
Read more

TerrAscend Announces Second Quarter 2018 Financial Results

TerrAscend Announces Second Quarter 2018 Financial Results
TerrAscend Announces Second Quarter 2018 Financial Results /NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRES/ TORONTO, Aug. 28, 2018 /CNW/ - TerrAscend Corp. (CSE:TER) ("TerrAscend" or the "Company") today reported financial results for the second quarter, ending June 30, 2018. Financial results and analyses are available on the Company's website (www.terrascend.com) and SEDAR (www.sedar.com). TerrAscend continued to execute on its business…
Read more